Lisanne F van Dessel
Overview
Explore the profile of Lisanne F van Dessel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
286
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isebia K, de Jong A, van Dessel L, de Weerd V, Beaufort C, Helmijr J, et al.
Mol Oncol
. 2025 Mar;
PMID: 40084488
Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration-resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test-sequencing...
2.
Deger T, Boers R, de Weerd V, Angus L, van der Put M, Boers J, et al.
Clin Epigenetics
. 2021 Oct;
13(1):196.
PMID: 34670587
Background: DNA methylation detection in liquid biopsies provides a highly promising and much needed means for real-time monitoring of disease load in advanced cancer patient care. Compared to the often-used...
3.
Espejo Valle-Inclan J, Stangl C, de Jong A, van Dessel L, van Roosmalen M, Helmijr J, et al.
Genome Med
. 2021 May;
13(1):86.
PMID: 34006333
Here, we describe a novel approach for rapid discovery of a set of tumor-specific genomic structural variants (SVs), based on a combination of low coverage cancer genome sequencing using Oxford...
4.
Snaterse G, van Dessel L, van Riet J, Taylor A, van der Vlugt-Daane M, Hamberg P, et al.
JCI Insight
. 2021 May;
6(11).
PMID: 33974560
BACKGROUNDContinued androgen receptor (AR) signaling constitutes a key target for treatment in metastatic castration-resistant prostate cancer (CRPC). Studies have identified 11-ketotestosterone (11KT) as a potent AR agonist, but it is...
5.
Mout L, van Dessel L, Kraan J, de Jong A, Neves R, Erkens-Schulze S, et al.
Eur J Cancer
. 2021 May;
150:179-189.
PMID: 33932725
Background: Circulating tumour cell (CTC)-derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here,...
6.
Vitale S, Helmijr J, Gerritsen M, Coban H, van Dessel L, Beije N, et al.
BMC Cancer
. 2021 Mar;
21(1):315.
PMID: 33761899
Background: Extracellular vesicles (EVs) are actively secreted by cells into body fluids and contain nucleic acids of the cells they originate from. The goal of this study was to detect...
7.
Snaterse G, van Dessel L, Taylor A, Visser J, Arlt W, Lolkema M, et al.
Steroids
. 2021 Feb;
167:108800.
PMID: 33556368
Background: Steroid hormones are essential signalling molecules in prostate cancer (PC). However, many studies focusing on liquid biomarkers fail to take the hormonal status of these patients into account. Steroid...
8.
van Dessel L, Martens J, Lolkema M
Curr Opin Oncol
. 2020 Jul;
32(5):527-534.
PMID: 32675591
Purpose Of Review: In this review, we provide an overview of the recent developments and prospects on the applications of blood-based liquid biopsies, including circulating tumor DNA and circulating tumor...
9.
van Dessel L, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden M, et al.
Nat Commun
. 2019 Nov;
10(1):5251.
PMID: 31748536
Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomic landscape. With the recent development of novel treatments, accurate stratification strategies are needed. Here we present the whole-genome sequencing (WGS)...
10.
van Dessel L, Vitale S, Helmijr J, Wilting S, van der Vlugt-Daane M, Oomen-de Hoop E, et al.
Mol Oncol
. 2018 Dec;
13(2):392-402.
PMID: 30516338
The emerging interest in circulating tumor DNA (ctDNA) analyses for clinical trials has necessitated the development of a high-throughput method for fast, reproducible, and efficient isolation of ctDNA. Currently, the...